Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inhaled JAK1 inhibitor
- Development stage
- Preclinical
- Lead developer
- Chiesi
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Chiesi's inhaled JAK1 inhibitor is a preclinical-stage, lung-directed small molecule designed to selectively inhibit Janus kinase 1 (JAK1) within the pulmonary tissue. By targeting JAK1 locally via inhalation, the therapeutic aims to maximize local efficacy in the lungs while minimizing systemic exposure and the associated side effects of systemic JAK inhibition. In preclinical evaluations, including 3D air-liquid interface (ALI) human bronchial epithelial cell cultures and rodent models, the compound has demonstrated potent inhibition of IL-13-driven goblet cell hyperplasia, mucus hypersecretion, and airway remodeling. It is under development for the treatment of chronic inflammatory respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis.
- Other names
- Chiesi inhaled JAK1 inhibitorChiesi's inhaled JAK1 inhibitor
02
Targets
Beyond the preview
Go deeper on inhaled JAK1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inhaled JAK1 inhibitor.